Agendia to Present New FLEX Study Data at ASCO 2026 Supporting NCCN Clinical Practice Guidelines in Oncology Update Recognizing MammaPrint for Guiding Anthracycline Use in Early-Stage Breast Cancer

May 21, 2026 Los Angeles Biotechnology Network News Los Angeles Biotech News Comments Off on Agendia to Present New FLEX Study Data at ASCO 2026 Supporting NCCN Clinical Practice Guidelines in Oncology Update Recognizing MammaPrint for Guiding Anthracycline Use in Early-Stage Breast Cancer

IRVINE, Calif. & AMSTERDAM–(BUSINESS WIRE)–Agendia will present two posters highlighting how its tests provide insights into treatment response and aid therapeutic decision-making for EBC.
Click here to view original post

Click Here to Publish/Feature Your Company or Product News with Biotech Networks